zhenwang zhang

Dr. zhenwang zhang

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2025 in Cytokine & Growth Factor Reviews
Verified
Journal Article
Closed access
SWSongsong Wu
Songsong Wu
ZCZhumin Cao
Zhumin Cao
RLRongying Lu
Rongying Lu
ZZzhenwang zhang
zhenwang zhang
Gautam SethiGautam Sethi
Gautam Sethi
YYYulai You
Yulai You

15 May 2025 in Cytokine & Growth Factor Reviews
Verified
Journal Article
Closed access
WLWen Luo
Wen Luo
QSQingfeng Shi
Qingfeng Shi
MHMingming Han
Mingming Han
ZZzhenwang zhang
zhenwang zhang
RRRussel J. Reiter
Russel J. Reiter
YMYing Mao
Ying Mao

26 September 2022 in Cancer Genetics
Verified
Journal Article
Closed access
WJWang Jiawei
Wang Jiawei
BXBao Xiajun
Bao Xiajun
STSun Tian
Sun Tian
GXGao Xuzheng
Gao Xuzheng
ZZzhenwang zhang
zhenwang zhang

5 January 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
MLMengxi Li
Mengxi Li
TWTingting Wang
Tingting Wang
ZZzhenwang zhang
zhenwang zhang
YDYuxi Dongye
Yuxi Dongye
Metabolic reprogramming has emerged as a central determinant of immune modulation in the post-metastatic tumor immune microenvironment (TIME). Alterations in glycolysis and lactate accumulation, lipid metabolic rewiring, metal-dependent cell death pathways such as ferroptosis and cuproptosis, and the tryptophan–IDO1–kynurenine axis collectively contribute to an immunosuppressive niche that drives tumor progression and therapeutic resistance. These metabolic shifts are not isolated events but are intricately connected with immune-regulatory networks, profoundly influencing the efficacy of immunotherapy. Advances in multi-omics technologies—including metabolomics, proteomics, single-cell sequencing, and spatial omics—have provided unprecedented resolution to decode these complex interactions, enabling the identification of predictive biomarkers, delineation of metabolic–immune signatures, and discovery of therapeutic vulnerabilities. Integrating these multi-layered datasets has paved the way for precision medicine strategies that tailor immunotherapy to patient-specific metabolic and immune contexts. Therapeutically, combining metabolic inhibitors with immune checkpoint blockade, exploiting ferroptosis or cuproptosis to enhance tumor immunogenicity, or modulating amino acid metabolism to reverse immune tolerance are promising strategies to overcome resistance and expand patient benefit. Looking forward, the integration of multi-omics-guided biomarkers, AI-driven analytics, and advanced delivery systems such as nanoparticles and engineered exosomes will accelerate the translation of these insights into clinical practice. Decoding the metabolism–immunity crosstalk through multi-omics not only advances our understanding of metastatic cancer biology but also paves the way for next-generation personalized and adaptive therapies that promise to enhance immunotherapy efficacy, prolong survival, and improve the quality of life for patients with advanced cancers.

1 January 2023 in Journal of Cancer
Verified
Journal Article
Open access
PDF file
XGXiaofeng Gao
Xiaofeng Gao
HBHuitong Bu
Huitong Bu
JGJuanjuan Ge
Juanjuan Ge
XGXuzheng Gao
Xuzheng Gao
YWYing Wang
Ying Wang
LWLong Wang
Long Wang
Background: Cyclin F (CCNF) represents a pivotal constituent within the family of cell cycle proteins, which also belongs to the F-box protein family and acts as a critical regulatory factor in cell cycle transition. Its heightened expression has been consistently identified across various cancer types, including breast, pancreatic, and colorectal cancer. Nonetheless, a comprehensive exploration of CCNF's involvement in pan-cancer remains lacking.

6 May 2023 in Separation and Purification Technology
Verified
Journal Article
Closed access
WQWenbin Qian
Wenbin Qian
MHMeichun Hu
Meichun Hu
YSYanting Su
Yanting Su
SSShigang Shan
Shigang Shan
ZZzhenwang zhang
zhenwang zhang
Xiaoqing LinXiaoqing Lin
Xiaoqing Lin